

Tsuyoshi Yokoi

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/3946523/tsuyoshi-yokoi-publications-by-year.pdf>

Version: 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

238
papers

11,161
citations

60
h-index

92
g-index

244
ext. papers

12,094
ext. citations

4.2
avg, IF

6.19
L-index

#	Paper	IF	Citations
238	Recent progress in the use of microRNAs as biomarkers for drug-induced toxicities in contrast to traditional biomarkers: A comparative review. <i>Drug Metabolism and Pharmacokinetics</i> , 2021 , 37, 100372	2.2	4
237	An in vitro coculture system of human peripheral blood mononuclear cells with hepatocellular carcinoma-derived cells for predicting drug-induced liver injury. <i>Archives of Toxicology</i> , 2021 , 95, 149-168	5.8	9
236	Models of Idiosyncratic Drug-Induced Liver Injury. <i>Annual Review of Pharmacology and Toxicology</i> , 2021 , 61, 247-268	17.9	8
235	Plasma miR-218a-5p as a biomarker for acute cholestatic liver injury in rats and investigation of its pathophysiological roles. <i>Journal of Applied Toxicology</i> , 2021 , 41, 1537-1552	4.1	0
234	Non-P450 Drug-Metabolizing Enzymes: Contribution to Drug Disposition, Toxicity, and Development. <i>Annual Review of Pharmacology and Toxicology</i> , 2021 ,	17.9	3
233	Exploration of small RNA biomarkers for testicular injury in the serum exosomes of rats. <i>Toxicology</i> , 2020 , 440, 152490	4.4	1
232	Macrophage-derived extracellular vesicles regulate concanavalin A-induced hepatitis by suppressing macrophage cytokine production. <i>Toxicology</i> , 2020 , 443, 152544	4.4	2
231	Pharmacological evidence for the involvement of ryanodine receptors in halothane-induced liver injury in mice. <i>Toxicology</i> , 2020 , 443, 152560	4.4	1
230	A scrutiny of circulating microRNA biomarkers for drug-induced tubular and glomerular injury in rats. <i>Toxicology</i> , 2019 , 415, 26-36	4.4	11
229	Analysis of a Skeletal Muscle Injury and Drug Interactions in Lovastatin- and Fenofibrate-Coadministered Dogs. <i>International Journal of Toxicology</i> , 2019 , 38, 192-201	2.4	2
228	Characterization of human UGT2A3 expression using a prepared specific antibody against UGT2A3. <i>Drug Metabolism and Pharmacokinetics</i> , 2019 , 34, 280-286	2.2	0
227	Establishment and characterization of a mouse model of rhabdomyolysis by coadministration of statin and fibrate. <i>Toxicology Letters</i> , 2019 , 307, 49-58	4.4	11
226	Establishment of a mouse model of troglitazone-induced liver injury and analysis of its hepatotoxic mechanism. <i>Journal of Applied Toxicology</i> , 2019 , 39, 1541-1556	4.1	4
225	Unique miRNA profiling of squamous cell carcinoma arising from ovarian mature teratoma: comprehensive miRNA sequence analysis of its molecular background. <i>Carcinogenesis</i> , 2019 , 40, 1435-1444	4.6	5
224	Acute kidney injury model established by systemic glutathione depletion in mice. <i>Journal of Applied Toxicology</i> , 2019 , 39, 919-930	4.1	3
223	Strain and interindividual differences in lamotrigine-induced liver injury in mice. <i>Journal of Applied Toxicology</i> , 2019 , 39, 451-460	4.1	3
222	Establishment of a drug-induced rhabdomyolysis mouse model by co-administration of ciprofloxacin and atorvastatin. <i>Toxicology Letters</i> , 2018 , 291, 184-193	4.4	10

221	miRNA in Rat Liver Sinusoidal Endothelial Cells and Hepatocytes and Application to Circulating Biomarkers that Discern Pathogenesis of Liver Injuries. <i>American Journal of Pathology</i> , 2018 , 188, 916-928	5.8	13
220	Cell-based assay using glutathione-depleted HepaRG and HepG2 human liver cells for predicting drug-induced liver injury. <i>Toxicology in Vitro</i> , 2018 , 48, 286-301	3.6	16
219	Role of cytochrome P450-mediated metabolism and involvement of reactive metabolite formations on antiepileptic drug-induced liver injuries. <i>Journal of Toxicological Sciences</i> , 2018 , 43, 75-87	1.9	13
218	Fluoroquinolones and propionic acid derivatives induce inflammatory responses in vitro. <i>Cell Biology and Toxicology</i> , 2018 , 34, 65-77	7.4	4
217	Comprehensive analysis of serum microRNAs in hepatic sinusoidal obstruction syndrome (SOS) in rats: implication as early phase biomarkers for SOS. <i>Archives of Toxicology</i> , 2018 , 92, 2947-2962	5.8	8
216	Identification of Specific MicroRNA Biomarkers in Early Stages of Hepatocellular Injury, Cholestasis, and Steatosis in Rats. <i>Toxicological Sciences</i> , 2018 , 166, 228-239	4.4	21
215	Neutrophil depletion protects against zomepirac-induced acute kidney injury in mice. <i>Chemico-Biological Interactions</i> , 2018 , 279, 102-110	5	1
214	Comparative hepatic transcriptome analyses revealed possible pathogenic mechanisms of fasiglifam (TAK-875)-induced acute liver injury in mice. <i>Chemico-Biological Interactions</i> , 2018 , 296, 185-197	5	7
213	Establishment of a novel mouse model for pioglitazone-induced skeletal muscle injury. <i>Toxicology</i> , 2017 , 382, 1-9	4.4	8
212	Establishment of a mouse model of enalapril-induced liver injury and investigation of the pathogenesis. <i>Laboratory Investigation</i> , 2017 , 97, 833-842	5.9	5
211	Toxicological potential of acyl glucuronides and its assessment. <i>Drug Metabolism and Pharmacokinetics</i> , 2017 , 32, 2-11	2.2	35
210	Serum microRNA profiles in patients with chronic hepatitis B, chronic hepatitis C, primary biliary cirrhosis, autoimmune hepatitis, nonalcoholic steatohepatitis, or drug-induced liver injury. <i>Clinical Biochemistry</i> , 2017 , 50, 1034-1039	3.5	13
209	Evaluation of expression and glycosylation status of UGT1A10 in Supersomes and intestinal epithelial cells with a novel specific UGT1A10 monoclonal antibody. <i>Drug Metabolism and Disposition</i> , 2017 , 45, 1027-1034	4	7
208	A modified multiparametric assay using HepaRG cells for predicting the degree of drug-induced liver injury risk. <i>Journal of Applied Toxicology</i> , 2017 , 37, 382-390	4.1	14
207	Toxicological role of an acyl glucuronide metabolite in diclofenac-induced acute liver injury in mice. <i>Journal of Applied Toxicology</i> , 2017 , 37, 545-553	4.1	22
206	Recent Progress and Prospect of Drug Metabolism/Pharmacokinetics Research Contributing to Drug Development. <i>Kagaku To Seibutsu</i> , 2017 , 55, 412-420	0	
205	MicroRNA-mediated Th2 bias in methimazole-induced acute liver injury in mice. <i>Toxicology and Applied Pharmacology</i> , 2016 , 307, 1-9	4.6	8
204	Kupffer cell-mediated exacerbation of methimazole-induced acute liver injury in rats. <i>Journal of Applied Toxicology</i> , 2016 , 36, 702-15	4.1	19

203	Zomepirac Acyl Glucuronide Is Responsible for Zomepirac-Induced Acute Kidney Injury in Mice. <i>Drug Metabolism and Disposition</i> , 2016 , 44, 888-96	4	16
202	Inhibitory and inductive effects of Phikud Navakot extract on human cytochrome P450. <i>Drug Metabolism and Pharmacokinetics</i> , 2016 , 31, 210-7	2.2	6
201	Allopurinol induces innate immune responses through mitogen-activated protein kinase signaling pathways in HL-60 cells. <i>Journal of Applied Toxicology</i> , 2016 , 36, 1120-8	4.1	6
200	Pathogenetic analyses of carbamazepine-induced liver injury in F344 rats focused on immune- and inflammation-related factors. <i>Experimental and Toxicologic Pathology</i> , 2016 , 68, 27-38		9
199	A novel cell-based assay for the evaluation of immune- and inflammatory-related gene expression as biomarkers for the risk assessment of drug-induced liver injury. <i>Toxicology Letters</i> , 2016 , 241, 60-70	4.4	25
198	Structure and Protein-Protein Interactions of Human UDP-Glucuronosyltransferases. <i>Frontiers in Pharmacology</i> , 2016 , 7, 388	5.6	33
197	Establishment of a mouse model for amiodarone-induced liver injury and analyses of its hepatotoxic mechanism. <i>Journal of Applied Toxicology</i> , 2016 , 36, 35-47	4.1	16
196	Multiparametric assay using HepaRG cells for predicting drug-induced liver injury. <i>Toxicology Letters</i> , 2015 , 236, 16-24	4.4	35
195	Nobiletin, a citrus flavonoid, improves cognitive impairment and reduces soluble A β levels in a triple transgenic mouse model of Alzheimer's disease (3XTg-AD). <i>Behavioural Brain Research</i> , 2015 , 289, 69-77	3.4	87
194	Targeted screen for human UDP-glucuronosyltransferases inhibitors and the evaluation of potential drug-drug interactions with zafirlukast. <i>Drug Metabolism and Disposition</i> , 2015 , 43, 812-8	4	16
193	Involvement of immune- and inflammatory-related factors in flucloxacillin-induced liver injury in mice. <i>Journal of Applied Toxicology</i> , 2015 , 35, 142-51	4.1	19
192	A comprehensive review of UDP-glucuronosyltransferase and esterases for drug development. <i>Drug Metabolism and Pharmacokinetics</i> , 2015 , 30, 30-51	2.2	147
191	Role of cytochrome P450-mediated metabolism and identification of novel thiol-conjugated metabolites in mice with phenytoin-induced liver injury. <i>Toxicology Letters</i> , 2015 , 232, 79-88	4.4	2
190	Allyl isothiocyanate (AITC) inhibits pregnane X receptor (PXR) and constitutive androstane receptor (CAR) activation and protects against acetaminophen- and amiodarone-induced cytotoxicity. <i>Archives of Toxicology</i> , 2015 , 89, 57-72	5.8	20
189	CYP2A7 pseudogene transcript affects CYP2A6 expression in human liver by acting as a decoy for miR-126. <i>Drug Metabolism and Disposition</i> , 2015 , 43, 703-12	4	32
188	Carbamazepine-Induced Liver Injury Requires CYP3A-Mediated Metabolism and Glutathione Depletion in Rats. <i>Drug Metabolism and Disposition</i> , 2015 , 43, 958-68	4	26
187	Toxicological evaluation of acyl glucuronides utilizing half-lives, peptide adducts, and immunostimulation assays. <i>Toxicology in Vitro</i> , 2015 , 30, 241-9	3.6	20
186	Involvement of oxidative stress and immune- and inflammation-related factors in azathioprine-induced liver injury. <i>Toxicology Letters</i> , 2014 , 224, 215-24	4.4	18

185	Regulation of cytochrome b5 expression by miR-223 in human liver: effects on cytochrome P450 activities. <i>Pharmaceutical Research</i> , 2014 , 31, 780-94	4.5	22
184	Evaluation and mechanistic analysis of the cytotoxicity of the acyl glucuronide of nonsteroidal anti-inflammatory drugs. <i>Drug Metabolism and Disposition</i> , 2014 , 42, 1-8	4	31
183	Indiplon is hydrolyzed by arylacetamide deacetylase in human liver. <i>Drug Metabolism and Disposition</i> , 2014 , 42, 751-8	4	14
182	Screening of specific inhibitors for human carboxylesterases or arylacetamide deacetylase. <i>Drug Metabolism and Disposition</i> , 2014 , 42, 1103-9	4	62
181	Development of a cell-based assay system considering drug metabolism and immune- and inflammatory-related factors for the risk assessment of drug-induced liver injury. <i>Toxicology Letters</i> , 2014 , 228, 13-24	4.4	23
180	Epigenetic regulation of the tissue-specific expression of human UDP-glucuronosyltransferase (UGT) 1A10. <i>Biochemical Pharmacology</i> , 2014 , 87, 660-7	6	27
179	An orphan esterase ABHD10 modulates probenecid acyl glucuronidation in human liver. <i>Drug Metabolism and Disposition</i> , 2014 , 42, 2109-16	4	14
178	P-glycoprotein, CYP3A, and plasma carboxylesterase determine brain and blood disposition of the mTOR Inhibitor everolimus (Afinitor) in mice. <i>Clinical Cancer Research</i> , 2014 , 20, 3133-45	12.9	23
177	Retinoid X receptor β in human liver is regulated by miR-34a. <i>Biochemical Pharmacology</i> , 2014 , 90, 179-87	6	35
176	N-Glycosylation during translation is essential for human arylacetamide deacetylase enzyme activity. <i>Biochemical Pharmacology</i> , 2014 , 87, 352-9	6	8
175	Involvement of miRNAs in the early phase of halothane-induced liver injury. <i>Toxicology</i> , 2014 , 319, 75-84	4.4	16
174	Changes in the expression of miRNAs at the pericentral and periportal regions of the rat liver in response to hepatocellular injury: comparison with the changes in the expression of plasma miRNAs. <i>Toxicology</i> , 2014 , 322, 89-98	4.4	9
173	Development of mice exhibiting hepatic microsomal activity of human CYP3A4 comparable to that in human liver microsomes by intravenous administration of an adenovirus vector expressing human CYP3A4. <i>Drug Metabolism and Pharmacokinetics</i> , 2014 , 29, 296-304	2.2	1
172	MicroRNA: Regulation of P450 and Pharmacogenetics 2014 , 385-401		1
171	Inhibition of cytochrome P450 2C9 expression and activity in vitro by allyl isothiocyanate. <i>Planta Medica</i> , 2014 , 80, 1097-106	3.1	8
170	Integrated analysis of rifampicin-induced microRNA and gene expression changes in human hepatocytes. <i>Drug Metabolism and Pharmacokinetics</i> , 2014 , 29, 333-40	2.2	23
169	microRNAs as mediators of drug toxicity. <i>Annual Review of Pharmacology and Toxicology</i> , 2013 , 53, 377-409	4.9	94
168	Cigarette smoking substantially alters plasma microRNA profiles in healthy subjects. <i>Toxicology and Applied Pharmacology</i> , 2013 , 272, 154-60	4.6	91

167	A novel mouse model for phenytoin-induced liver injury: involvement of immune-related factors and P450-mediated metabolism. <i>Toxicological Sciences</i> , 2013 , 136, 250-63	4.4	22
166	Human UDP-glucuronosyltransferase (UGT) 2B10 in drug N-glucuronidation: substrate screening and comparison with UGT1A3 and UGT1A4. <i>Drug Metabolism and Disposition</i> , 2013 , 41, 1389-97	4	41
165	Prilocaine- and lidocaine-induced methemoglobinemia is caused by human carboxylesterase-, CYP2E1-, and CYP3A4-mediated metabolic activation. <i>Drug Metabolism and Disposition</i> , 2013 , 41, 1220-30	4	33
164	Epigenetic regulation is a crucial factor in the repression of UGT1A1 expression in the human kidney. <i>Drug Metabolism and Disposition</i> , 2013 , 41, 1738-43	4	28
163	Establishment of MDCKII cell monolayer with metabolic activity by CYP3A4 transduced with recombinant adenovirus. <i>Drug Metabolism and Pharmacokinetics</i> , 2013 , 28, 125-31	2.2	4
162	Aryl hydrocarbon receptor nuclear translocator in human liver is regulated by miR-24. <i>Toxicology and Applied Pharmacology</i> , 2012 , 260, 222-31	4.6	36
161	Involvement of immune-related factors in diclofenac-induced acute liver injury in mice. <i>Toxicology</i> , 2012 , 293, 107-114	4.4	53
160	Preparation of a specific monoclonal antibody against human UDP-glucuronosyltransferase (UGT) 1A9 and evaluation of UGT1A9 protein levels in human tissues. <i>Drug Metabolism and Disposition</i> , 2012 , 40, 1620-7	4	27
159	Human UDP-glucuronosyltransferase isoforms involved in haloperidol glucuronidation and quantitative estimation of their contribution. <i>Drug Metabolism and Disposition</i> , 2012 , 40, 240-8	4	30
158	Metabolic activation and inflammation reactions involved in carbamazepine-induced liver injury. <i>Toxicological Sciences</i> , 2012 , 130, 4-16	4.4	46
157	Chimeric mice with a humanized liver as an animal model of troglitazone-induced liver injury. <i>Toxicology Letters</i> , 2012 , 214, 9-18	4.4	36
156	Metabolic activation by human arylacetamide deacetylase, CYP2E1, and CYP1A2 causes phenacetin-induced methemoglobinemia. <i>Biochemical Pharmacology</i> , 2012 , 84, 1196-206	6	15
155	Mechanisms of the hepatoprotective effects of tamoxifen against drug-induced and chemical-induced acute liver injuries. <i>Toxicology and Applied Pharmacology</i> , 2012 , 264, 42-50	4.6	16
154	Effects of <i>Phyllanthus amarus</i> on the pharmacokinetics of midazolam and cytochrome P450 activities in rats. <i>Xenobiotica</i> , 2012 , 42, 641-8	2	5
153	Involvement of Th2 cytokines in the mouse model of flutamide-induced acute liver injury. <i>Journal of Applied Toxicology</i> , 2012 , 32, 815-22	4.1	22
152	Th2 cytokine-mediated methimazole-induced acute liver injury in mice. <i>Journal of Applied Toxicology</i> , 2012 , 32, 823-33	4.1	27
151	A novel polymorphic allele of human arylacetamide deacetylase leads to decreased enzyme activity. <i>Drug Metabolism and Disposition</i> , 2012 , 40, 1183-90	4	21
150	Species differences in tissue distribution and enzyme activities of arylacetamide deacetylase in human, rat, and mouse. <i>Drug Metabolism and Disposition</i> , 2012 , 40, 671-9	4	47

149	Effects of silver nanoparticles on rat hepatic cytochrome P450 enzyme activity. <i>Xenobiotica</i> , 2012 , 42, 854-62	2	46
148	Human β -hydrolase domain containing 10 (ABHD10) is responsible enzyme for deglucuronidation of mycophenolic acid acyl-glucuronide in liver. <i>Journal of Biological Chemistry</i> , 2012 , 287, 9240-9	5.4	26
147	Contributions of arylacetamide deacetylase and carboxylesterase 2 to flutamide hydrolysis in human liver. <i>Drug Metabolism and Disposition</i> , 2012 , 40, 1080-4	4	32
146	Mechanism of exacerbative effect of progesterone on drug-induced liver injury. <i>Toxicological Sciences</i> , 2012 , 126, 16-27	4.4	20
145	Stimulation of human monocytic THP-1 cells by metabolic activation of hepatotoxic drugs. <i>Drug Metabolism and Pharmacokinetics</i> , 2012 , 27, 621-30	2.2	11
144	Hepatoprotective effect of tamoxifen on steatosis and non-alcoholic steatohepatitis in mouse models. <i>Journal of Toxicological Sciences</i> , 2012 , 37, 931-42	1.9	23
143	The emerging role of human esterases. <i>Drug Metabolism and Pharmacokinetics</i> , 2012 , 27, 466-77	2.2	144
142	Plasma microRNA profiles in rat models of hepatocellular injury, cholestasis, and steatosis. <i>PLoS ONE</i> , 2012 , 7, e30250	3.7	74
141	IL-4 mediates dicloxacillin-induced liver injury in mice. <i>Toxicology Letters</i> , 2011 , 200, 139-45	4.4	32
140	Estradiol and progesterone modulate halothane-induced liver injury in mice. <i>Toxicology Letters</i> , 2011 , 204, 17-24	4.4	23
139	Interpretation of the effects of protein kinase C inhibitors on human UDP-glucuronosyltransferase 1A (UGT1A) proteins in cellulo. <i>Drug Metabolism and Pharmacokinetics</i> , 2011 , 26, 256-65	2.2	8
138	Current topics in drug metabolism and drug toxicity. Preface. <i>Drug Metabolism and Pharmacokinetics</i> , 2011 , 26, 1-2	2.2	1
137	MicroRNAs from biology to future pharmacotherapy: regulation of cytochrome P450s and nuclear receptors. <i>Pharmacology & Therapeutics</i> , 2011 , 131, 330-7	13.9	53
136	Human CYP2A6 is regulated by nuclear factor-erythroid 2 related factor 2. <i>Biochemical Pharmacology</i> , 2011 , 81, 289-94	6	35
135	Human arylacetamide deacetylase is responsible for deacetylation of rifamycins: rifampicin, rifabutin, and rifapentine. <i>Biochemical Pharmacology</i> , 2011 , 82, 1747-56	6	78
134	Progesterone receptor membrane component 1 modulates human cytochrome p450 activities in an isoform-dependent manner. <i>Drug Metabolism and Disposition</i> , 2011 , 39, 2057-65	4	25
133	PPAR α s regulated by miR-21 and miR-27b in human liver. <i>Pharmaceutical Research</i> , 2011 , 28, 2467-76	4.5	102
132	Stimulation of pro-inflammatory responses by mebendazole in human monocytic THP-1 cells through an ERK signaling pathway. <i>Archives of Toxicology</i> , 2011 , 85, 199-207	5.8	21

131	Human paraoxonase 1 is the enzyme responsible for pilocarpine hydrolysis. <i>Drug Metabolism and Disposition</i> , 2011 , 39, 1345-52	4	29
130	Toxicological implications of modulation of gene expression by microRNAs. <i>Toxicological Sciences</i> , 2011 , 123, 1-14	4.4	66
129	Toxicological evaluation of acyl glucuronides of nonsteroidal anti-inflammatory drugs using human embryonic kidney 293 cells stably expressing human UDP-glucuronosyltransferase and human hepatocytes. <i>Drug Metabolism and Disposition</i> , 2011 , 39, 54-60	4	39
128	Development of a highly sensitive cytotoxicity assay system for CYP3A4-mediated metabolic activation. <i>Drug Metabolism and Disposition</i> , 2011 , 39, 1388-95	4	42
127	CYP2C9-mediated metabolic activation of losartan detected by a highly sensitive cell-based screening assay. <i>Drug Metabolism and Disposition</i> , 2011 , 39, 838-46	4	30
126	In vitro investigation of the glutathione transferase M1 and T1 null genotypes as risk factors for troglitazone-induced liver injury. <i>Drug Metabolism and Disposition</i> , 2011 , 39, 1303-10	4	8
125	Immunohistochemical analysis of CYP2A13 in various types of human lung cancers. <i>Cancer Science</i> , 2010 , 101, 1024-8	6.9	13
124	Troglitazone. <i>Handbook of Experimental Pharmacology</i> , 2010 , 419-35	3.2	38
123	In vitro evaluation of inhibitory effects of antidiabetic and antihyperlipidemic drugs on human carboxylesterase activities. <i>Drug Metabolism and Disposition</i> , 2010 , 38, 2173-8	4	65
122	MicroRNAs regulate human hepatocyte nuclear factor 4alpha, modulating the expression of metabolic enzymes and cell cycle. <i>Journal of Biological Chemistry</i> , 2010 , 285, 4415-22	5.4	119
121	Arylacetamide deacetylase is a determinant enzyme for the difference in hydrolase activities of phenacetin and acetaminophen. <i>Drug Metabolism and Disposition</i> , 2010 , 38, 1532-7	4	49
120	Terbinafine stimulates the pro-inflammatory responses in human monocytic THP-1 cells through an ERK signaling pathway. <i>Life Sciences</i> , 2010 , 87, 537-44	6.8	15
119	An in vitro drug-induced hepatotoxicity screening system using CYP3A4-expressing and gamma-glutamylcysteine synthetase knockdown cells. <i>Toxicology in Vitro</i> , 2010 , 24, 1032-8	3.6	33
118	Recommended nomenclature for five mammalian carboxylesterase gene families: human, mouse, and rat genes and proteins. <i>Mammalian Genome</i> , 2010 , 21, 427-41	3.2	123
117	Interleukin-17 is involved in alpha-naphthylisothiocyanate-induced liver injury in mice. <i>Toxicology</i> , 2010 , 275, 50-7	4.4	28
116	Transcriptional regulation of human carboxylesterase 1A1 by nuclear factor-erythroid 2 related factor 2 (Nrf2). <i>Biochemical Pharmacology</i> , 2010 , 79, 288-95	6	28
115	Human CYP2E1 is regulated by miR-378. <i>Biochemical Pharmacology</i> , 2010 , 79, 1045-52	6	133
114	N-Glycosylation plays a role in protein folding of human UGT1A9. <i>Biochemical Pharmacology</i> , 2010 , 79, 1165-72	6	32

113	Interactions between human UDP-glucuronosyltransferase (UGT) 2B7 and UGT1A enzymes. <i>Journal of Pharmaceutical Sciences</i> , 2010 , 99, 442-54	3.9	32
112	Expression of cytochrome P450 (CYP) enzymes in human nonpigmented ciliary epithelial cells: induction of CYP1B1 expression by TCDD 2009 , 50, 3099-105		17
111	Different inhibitory effects in rat and human carboxylesterases. <i>Drug Metabolism and Disposition</i> , 2009 , 37, 956-61	4	44
110	Human arylacetamide deacetylase is a principal enzyme in flutamide hydrolysis. <i>Drug Metabolism and Disposition</i> , 2009 , 37, 1513-20	4	60
109	Halothane-induced liver injury is mediated by interleukin-17 in mice. <i>Toxicological Sciences</i> , 2009 , 111, 302-10	4.4	56
108	Metabolic activation of benzodiazepines by CYP3A4. <i>Drug Metabolism and Disposition</i> , 2009 , 37, 345-51	4	31
107	Human CYP24 catalyzing the inactivation of calcitriol is post-transcriptionally regulated by miR-125b. <i>Molecular Pharmacology</i> , 2009 , 76, 702-9	4.3	119
106	MicroRNA regulates human vitamin D receptor. <i>International Journal of Cancer</i> , 2009 , 125, 1328-33	7.5	160
105	Identification of urinary biomarkers useful for distinguishing a difference in mechanism of toxicity in rat model of cholestasis. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2009 , 105, 156-66	3.1	13
104	Knockdown of superoxide dismutase 2 enhances acetaminophen-induced hepatotoxicity in rat. <i>Toxicology</i> , 2009 , 264, 89-95	4.4	21
103	Quantitative analysis of UDP-glucuronosyltransferase (UGT) 1A and UGT2B expression levels in human livers. <i>Drug Metabolism and Disposition</i> , 2009 , 37, 1759-68	4	190
102	Key amino acid residues responsible for the differences in substrate specificity of human UDP-glucuronosyltransferase (UGT)1A9 and UGT1A8. <i>Drug Metabolism and Disposition</i> , 2009 , 37, 41-6	4	18
101	Establishment of knockdown of superoxide dismutase 2 and expression of CYP3A4 cell system to evaluate drug-induced cytotoxicity. <i>Toxicology in Vitro</i> , 2009 , 23, 1179-87	3.6	22
100	Drug-induced hepatotoxicity test using gamma-glutamylcysteine synthetase knockdown rat. <i>Toxicology Letters</i> , 2009 , 189, 159-65	4.4	21
99	Essentials for starting a pediatric clinical study (1): Pharmacokinetics in children. <i>Journal of Toxicological Sciences</i> , 2009 , 34 Suppl 2, SP307-12	1.9	33
98	Effects of Japanese herbal medicine, Kampo, on human UGT1A1 activity. <i>Drug Metabolism and Pharmacokinetics</i> , 2009 , 24, 226-34	2.2	20
97	In silico and in vitro approaches to elucidate the thermal stability of human UDP-glucuronosyltransferase (UGT) 1A9. <i>Drug Metabolism and Pharmacokinetics</i> , 2009 , 24, 235-44	2.2	24
96	Inhibitory effects of Kampo medicine on human UGT2B7 activity. <i>Drug Metabolism and Pharmacokinetics</i> , 2009 , 24, 490-9	2.2	8

95	Human cytochrome P450 2A13 efficiently metabolizes chemicals in air pollutants: naphthalene, styrene, and toluene. <i>Chemical Research in Toxicology</i> , 2008 , 21, 720-5	4	60
94	Human hepatocytes can repopulate mouse liver: histopathology of the liver in human hepatocyte-transplanted chimeric mice and toxicologic responses to acetaminophen. <i>Toxicologic Pathology</i> , 2008 , 36, 581-91	2.1	22
93	Product inhibition of UDP-glucuronosyltransferase (UGT) enzymes by UDP obfuscates the inhibitory effects of UGT substrates. <i>Drug Metabolism and Disposition</i> , 2008 , 36, 361-7	4	33
92	Post-transcriptional regulation of human pregnane X receptor by micro-RNA affects the expression of cytochrome P450 3A4. <i>Journal of Biological Chemistry</i> , 2008 , 283, 9674-80	5.4	219
91	Species differences in UDP-glucuronosyltransferase activities in mice and rats. <i>Drug Metabolism and Disposition</i> , 2008 , 36, 1745-52	4	71
90	Regulation of insulin-like growth factor binding protein-1 and lipoprotein lipase by the aryl hydrocarbon receptor. <i>Journal of Toxicological Sciences</i> , 2008 , 33, 405-13	1.9	15
89	Genetic polymorphisms of CYP2A6 affect the in-vivo pharmacokinetics of pilocarpine. <i>Pharmacogenetics and Genomics</i> , 2008 , 18, 761-72	1.9	15
88	Genetic polymorphisms in the 5Sflanking region of human UDP-glucuronosyltransferase 2B7 affect the Nrf2-dependent transcriptional regulation. <i>Pharmacogenetics and Genomics</i> , 2008 , 18, 709-20	1.9	28
87	Structure and characterization of human carboxylesterase 1A1, 1A2, and 1A3 genes. <i>Pharmacogenetics and Genomics</i> , 2008 , 18, 911-20	1.9	64
86	Allosteric kinetics of human carboxylesterase 1: species differences and interindividual variability. <i>Journal of Pharmaceutical Sciences</i> , 2008 , 97, 5434-45	3.9	26
85	Chimeric mice with humanized liver. <i>Toxicology</i> , 2008 , 246, 9-17	4.4	78
84	Expression of UGT1A and UGT2B mRNA in human normal tissues and various cell lines. <i>Drug Metabolism and Disposition</i> , 2008 , 36, 1461-4	4	224
83	In vivo drug metabolism model for human cytochrome P450 enzyme using chimeric mice with humanized liver. <i>Journal of Pharmaceutical Sciences</i> , 2007 , 96, 428-37	3.9	58
82	Species differences of inhibitory effects on P-glycoprotein-mediated drug transport. <i>Journal of Pharmaceutical Sciences</i> , 2007 , 96, 1609-18	3.9	55
81	Change of drug excretory pathway by CCl4-induced liver dysfunction in rat. <i>Biochemical Pharmacology</i> , 2007 , 74, 488-95	6	18
80	Stereoselective glucuronidation of 5-(4Hydroxyphenyl)-5-phenylhydantoin by human UDP-glucuronosyltransferase (UGT) 1A1, UGT1A9, and UGT2B15: effects of UGT-UGT interactions. <i>Drug Metabolism and Disposition</i> , 2007 , 35, 1679-86	4	31
79	CYP2A13 metabolizes the substrates of human CYP1A2, phenacetin, and theophylline. <i>Drug Metabolism and Disposition</i> , 2007 , 35, 335-9	4	37
78	Knock down of gamma-glutamylcysteine synthetase in rat causes acetaminophen-induced hepatotoxicity. <i>Journal of Biological Chemistry</i> , 2007 , 282, 23996-4003	5.4	37

77	Effects of coexpression of UGT1A9 on enzymatic activities of human UGT1A isoforms. <i>Drug Metabolism and Disposition</i> , 2007 , 35, 747-57	4	65
76	Interactions between human UGT1A1, UGT1A4, and UGT1A6 affect their enzymatic activities. <i>Drug Metabolism and Disposition</i> , 2007 , 35, 1781-7	4	58
75	Glucuronidation of thyroxine in human liver, jejunum, and kidney microsomes. <i>Drug Metabolism and Disposition</i> , 2007 , 35, 1642-8	4	51
74	Human CYP2A6 is induced by estrogen via estrogen receptor. <i>Drug Metabolism and Disposition</i> , 2007 , 35, 1935-41	4	109
73	Inchinkoto, a herbal medicine, and its ingredients dually exert Mrp2/MRP2-mediated choleresis and Nrf2-mediated antioxidative action in rat livers. <i>American Journal of Physiology - Renal Physiology</i> , 2007 , 292, G1450-63	5.1	66
72	Humanization of excretory pathway in chimeric mice with humanized liver. <i>Toxicological Sciences</i> , 2007 , 97, 533-8	4.4	53
71	A novel duplication type of CYP2A6 gene in African-American population. <i>Drug Metabolism and Disposition</i> , 2007 , 35, 515-20	4	41
70	Glucuronidation of antiallergic drug, Tranilast: identification of human UDP-glucuronosyltransferase isoforms and effect of its phase I metabolite. <i>Drug Metabolism and Disposition</i> , 2007 , 35, 583-9	4	24
69	Inhibitory effects of neurotransmitters and steroids on human CYP2A6. <i>Drug Metabolism and Disposition</i> , 2007 , 35, 508-14	4	24
68	Genetic polymorphisms of CYP2B6 affect the pharmacokinetics/pharmacodynamics of cyclophosphamide in Japanese cancer patients. <i>Pharmacogenetics and Genomics</i> , 2007 , 17, 431-45	1.9	97
67	Morphine glucuronosyltransferase activity in human liver microsomes is inhibited by a variety of drugs that are co-administered with morphine. <i>Drug Metabolism and Pharmacokinetics</i> , 2007 , 22, 103-12	2.2	29
66	Bezafibrate induces multidrug-resistance P-Glycoprotein 3 expression in cultured human hepatocytes and humanized livers of chimeric mice. <i>Hepatology Research</i> , 2007 , 37, 548-56	5.1	23
65	Application of chimeric mice with humanized liver for predictive ADME. <i>Drug Metabolism Reviews</i> , 2007 , 39, 145-57	7	45
64	CYP2A13 expressed in human bladder metabolically activates 4-aminobiphenyl. <i>International Journal of Cancer</i> , 2006 , 119, 2520-6	7.5	56
63	Kinetic analyses for species differences in P-glycoprotein-mediated drug transport. <i>Journal of Pharmaceutical Sciences</i> , 2006 , 95, 2673-83	3.9	87
62	Evaluation of human CYP1A2 and CYP3A4 mRNA expression in hepatocytes from chimeric mice with humanized liver. <i>Drug Metabolism and Pharmacokinetics</i> , 2006 , 21, 465-74	2.2	19
61	Binding of steroidogenic factor-1 to the regulatory region might not be critical for transcriptional regulation of the human CYP1B1 gene. <i>Journal of Biochemistry</i> , 2006 , 139, 527-34	3.1	7
60	MicroRNA regulates the expression of human cytochrome P450 1B1. <i>Cancer Research</i> , 2006 , 66, 9090-8	10.1	335

59	Induction of human CYP2A6 is mediated by the pregnane X receptor with peroxisome proliferator-activated receptor-gamma coactivator 1alpha. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2006 , 319, 693-702	4.7	77
58	Dephosphorylation of ribosomal protein P0 in response to troglitazone-induced cytotoxicity. <i>Toxicology Letters</i> , 2006 , 166, 189-99	4.4	9
57	Simultaneous measurement of gene expression for hepatotoxicity in thioacetamide-administered rats by DNA microarrays. <i>Mutation Research - Genetic Toxicology and Environmental Mutagenesis</i> , 2006 , 603, 64-73	3	7
56	Decreased responsiveness of naturally occurring mutants of human estrogen receptor alpha to estrogens and antiestrogens. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2006 , 100, 79-86	5.1	8
55	Isoflavones inhibit nicotine C-oxidation catalyzed by human CYP2A6. <i>Journal of Clinical Pharmacology</i> , 2006 , 46, 337-44	2.9	24
54	Comprehensive evaluation of variability in nicotine metabolism and CYP2A6 polymorphic alleles in four ethnic populations. <i>Clinical Pharmacology and Therapeutics</i> , 2006 , 80, 282-97	6.1	175
53	Establishment and characterization of the transformants stably-expressing MDR1 derived from various animal species in LLC-PK1. <i>Pharmaceutical Research</i> , 2006 , 23, 1460-72	4.5	109
52	Induction of human CYP1A2 and CYP3A4 in primary culture of hepatocytes from chimeric mice with humanized liver. <i>Drug Metabolism and Pharmacokinetics</i> , 2005 , 20, 121-6	2.2	33
51	Cytochrome P450-mediated metabolism of estrogens and its regulation in human. <i>Cancer Letters</i> , 2005 , 227, 115-24	9.9	407
50	Pharmacokinetics of paclitaxel in ovarian cancer patients and genetic polymorphisms of CYP2C8, CYP3A4, and MDR1. <i>Journal of Clinical Pharmacology</i> , 2005 , 45, 674-82	2.9	56
49	Chaperone proteins involved in troglitazone-induced toxicity in human hepatoma cell lines. <i>Toxicological Sciences</i> , 2005 , 83, 293-302	4.4	23
48	Urinary excretion of phenytoin metabolites, 5-(4Hydroxyphenyl)-5-phenylhydantoin and its O-glucuronide in humans and analysis of genetic polymorphisms of UDP-glucuronosyltransferases. <i>Drug Metabolism and Pharmacokinetics</i> , 2005 , 20, 135-43	2.2	17
47	Inhibitory effects of nicardipine to cytochrome P450 (CYP) in human liver microsomes. <i>Biological and Pharmaceutical Bulletin</i> , 2005 , 28, 882-5	2.3	24
46	Detection of autoantibody to aldolase B in sera from patients with troglitazone-induced liver dysfunction. <i>Toxicology</i> , 2005 , 216, 15-23	4.4	24
45	A novel CYP2A6*20 allele found in African-American population produces a truncated protein lacking enzymatic activity. <i>Biochemical Pharmacology</i> , 2005 , 70, 801-8	6	43
44	Cancer pharmacogenomics: achievements in basic research. <i>International Journal of Clinical Oncology</i> , 2005 , 10, 14-9	4.2	6
43	Characterization of novel CYP2A6 polymorphic alleles (CYP2A6*18 and CYP2A6*19) that affect enzymatic activity. <i>Drug Metabolism and Disposition</i> , 2005 , 33, 1202-10	4	46
42	Interindividual variability in nicotine metabolism: C-oxidation and glucuronidation. <i>Drug Metabolism and Pharmacokinetics</i> , 2005 , 20, 227-35	2.2	71

41	In vivo induction of human cytochrome P450 enzymes expressed in chimeric mice with humanized liver. <i>Drug Metabolism and Disposition</i> , 2005 , 33, 754-63	4	51
40	CYP2A6 AND CYP2B6 are involved in nornicotine formation from nicotine in humans: interindividual differences in these contributions. <i>Drug Metabolism and Disposition</i> , 2005 , 33, 1811-8	4	48
39	Trans-3Hydroxycotinine O- and N-glucuronidations in human liver microsomes. <i>Drug Metabolism and Disposition</i> , 2005 , 33, 23-30	4	51
38	Expression of human phase II enzymes in chimeric mice with humanized liver. <i>Drug Metabolism and Disposition</i> , 2005 , 33, 1333-40	4	87
37	Relationship between hepatic gene expression profiles and hepatotoxicity in five typical hepatotoxicant-administered rats. <i>Toxicological Sciences</i> , 2005 , 87, 296-305	4.4	69
36	Expression of human cytochromes P450 in chimeric mice with humanized liver. <i>Drug Metabolism and Disposition</i> , 2004 , 32, 1402-10	4	99
35	Human CYP1B1 is regulated by estradiol via estrogen receptor. <i>Cancer Research</i> , 2004 , 64, 3119-25	10.1	200
34	Identification of the cytosolic carboxylesterase catalyzing the 5Sdeoxy-5-fluorocytidine formation from capecitabine in human liver. <i>Drug Metabolism and Disposition</i> , 2004 , 32, 1103-10	4	89
33	Bioactivation of capecitabine in human liver: involvement of the cytosolic enzyme on 5Sdeoxy-5-fluorocytidine formation. <i>Drug Metabolism and Disposition</i> , 2004 , 32, 762-7	4	48
32	Involvement of organic anion transporting polypeptides in the transport of troglitazone sulfate: implications for understanding troglitazone hepatotoxicity. <i>Drug Metabolism and Disposition</i> , 2004 , 32, 291-4	4	101
31	Tissue-specific mRNA expression profiles of human nuclear receptor subfamilies. <i>Drug Metabolism and Pharmacokinetics</i> , 2004 , 19, 135-49	2.2	138
30	Metabolic profile of nicotine in subjects whose CYP2A6 gene is deleted. <i>European Journal of Pharmaceutical Sciences</i> , 2004 , 22, 419-25	5.1	67
29	Role of the aryl hydrocarbon receptor and Cyp1b1 in the antiestrogenic activity of 2,3,7,8-tetrachlorodibenzo-p-dioxin. <i>Archives of Toxicology</i> , 2004 , 78, 309-15	5.8	22
28	A novel polymorphism of human CYP2A6 gene CYP2A6*17 has an amino acid substitution (V365M) that decreases enzymatic activity in vitro and in vivo. <i>Clinical Pharmacology and Therapeutics</i> , 2004 , 76, 519-27	6.1	65
27	Novel human CYP2A6 alleles confound gene deletion analysis. <i>FEBS Letters</i> , 2004 , 569, 75-81	3.8	37
26	Near completely humanized liver in mice shows human-type metabolic responses to drugs. <i>American Journal of Pathology</i> , 2004 , 165, 901-12	5.8	453
25	Glucuronidation of etoposide in human liver microsomes is specifically catalyzed by UDP-glucuronosyltransferase 1A1. <i>Drug Metabolism and Disposition</i> , 2003 , 31, 589-95	4	86
24	Effects of polymorphism in promoter region of human CYP2A6 gene (CYP2A6*9) on expression level of messenger ribonucleic acid and enzymatic activity in vivo and in vitro. <i>Clinical Pharmacology and Therapeutics</i> , 2003 , 74, 69-76	6.1	104

23	Critical enhancer region to which AhR/ARNT and Sp1 bind in the human CYP1B1 gene. <i>Journal of Biochemistry</i> , 2003 , 133, 583-92	3.1	57
22	Genetic polymorphisms of CYP2C8 in Japanese population. <i>Drug Metabolism and Disposition</i> , 2003 , 31, 687-90	4	65
21	Evaluation of approach to predict the contribution of multiple cytochrome P450s in drug metabolism using relative activity factor: effects of the differences in expression levels of NADPH-cytochrome P450 reductase and cytochrome b(5) in the expression system and the differences in the marker activities. <i>Journal of Pharmaceutical Sciences</i> , 2002 , 91, 952-63	3.9	45
20	Induction of CYP1A1, CYP1A2, and CYP1B1 mRNAs by nitropolycyclic aromatic hydrocarbons in various human tissue-derived cells: chemical-, cytochrome P450 isoform-, and cell-specific differences. <i>Archives of Toxicology</i> , 2002 , 76, 287-98	5.8	143
19	Genetic polymorphisms in human CYP2A6 gene causing impaired nicotine metabolism. <i>British Journal of Clinical Pharmacology</i> , 2002 , 54, 511-7	3.8	75
18	Formation of a novel quinone epoxide metabolite of troglitazone with cytotoxicity to HepG2 cells. <i>Drug Metabolism and Disposition</i> , 2002 , 30, 155-60	4	75
17	Characterization of nicotine and cotinine N-glucuronidations in human liver microsomes. <i>Drug Metabolism and Disposition</i> , 2002 , 30, 1484-90	4	41
16	Troglitazone glucuronidation in human liver and intestine microsomes: high catalytic activity of UGT1A8 and UGT1A10. <i>Drug Metabolism and Disposition</i> , 2002 , 30, 1462-9	4	74
15	Imipramine N-glucuronidation in human liver microsomes: biphasic kinetics and characterization of UDP-glucuronosyltransferase isoforms. <i>Drug Metabolism and Disposition</i> , 2002 , 30, 636-42	4	63
14	Interindividual differences in nicotine metabolism and genetic polymorphisms of human CYP2A6. <i>Drug Metabolism Reviews</i> , 2002 , 34, 865-77	7	60
13	Involvement of multiple UDP-glucuronosyltransferase 1A isoforms in glucuronidation of 5-(4S-hydroxyphenyl)-5-phenylhydantoin in human liver microsomes. <i>Drug Metabolism and Disposition</i> , 2002 , 30, 1250-6	4	27
12	Roles of NADPH-P450 reductase and apo- and holo-cytochrome b5 on xenobiotic oxidations catalyzed by 12 recombinant human cytochrome P450s expressed in membranes of Escherichia coli. <i>Protein Expression and Purification</i> , 2002 , 24, 329-37	2	201
11	Relationship between interindividual differences in nicotine metabolism and CYP2A6 genetic polymorphism in humans. <i>Clinical Pharmacology and Therapeutics</i> , 2001 , 69, 72-8	6.1	109
10	Cytotoxicity and apoptosis produced by troglitazone in human hepatoma cells. <i>Life Sciences</i> , 2001 , 70, 471-82	6.8	74
9	Nicotine metabolism and CYP2A6 allele frequencies in Koreans. <i>Pharmacogenetics and Genomics</i> , 2001 , 11, 317-23		83
8	Improved highly sensitive method for determination of nicotine and cotinine in human plasma by high-performance liquid chromatography. <i>Biomedical Applications</i> , 2000 , 742, 211-5		42
7	Inhibitory potencies of 1,4-dihydropyridine calcium antagonists to P-glycoprotein-mediated transport: comparison with the effects on CYP3A4. <i>Pharmaceutical Research</i> , 2000 , 17, 1189-97	4.5	67
6	Deficient cotinine formation from nicotine is attributed to the whole deletion of the CYP2A6 gene in humans. <i>Clinical Pharmacology and Therapeutics</i> , 2000 , 67, 57-69	6.1	76

- | | | | |
|---|---|-----|----|
| 5 | Bioactivation of diesel exhaust particle extracts and their major nitrated polycyclic aromatic hydrocarbon components, 1-nitropyrene and dinitropyrenes, by human cytochromes P450 1A1, 1A2, and 1B1. <i>Mutation Research - Genetic Toxicology and Environmental Mutagenesis</i> , 2000 , 472, 129-38 | 3 | 50 |
| 4 | Homologous unequal cross-over within the human CYP2A gene cluster as a mechanism for the deletion of the entire CYP2A6 gene associated with the poor metabolizer phenotype. <i>Journal of Biochemistry</i> , 1999 , 126, 402-7 | 3.1 | 49 |
| 3 | Effects of chronic administration of glucocorticoid on midazolam pharmacokinetics in humans. <i>Therapeutic Drug Monitoring</i> , 1999 , 21, 507-13 | 3.2 | 18 |
| 2 | Inhibition of UDP-glucuronosyltransferase by aglycons of natural glucuronides in kampo medicines using SN-38 as a substrate. <i>Japanese Journal of Cancer Research</i> , 1995 , 86, 985-9 | | 20 |
| 1 | A Mechanistic View of Troglitazone Hepatotoxicity299-311 | | |